Newsroom
Newsroom
Obducat’s world
Obducat customer Sorrento Therapeutics reports positive results
The biopharmaceutical company Sorrento Therapeutics reports positive trial results utilizing Sofusa Lymphatic Delivery of the biological medical product Etanercept after completing its first phase 1b human proof of concept study.
Obducat gives presentation on ”Nanoimprint Lithography (NIL)-Based Patterning of Chemically Strengthened Glass Sheets”
The presentation will be held at the EIPBN conference - 65th International Conference on Electron, Ion and Photon Beam Technology and Nanofabrication, which will take place between May 31 and June 3, 2022, in New Orleans, Louisiana.
Is this where your Obducat story begins? We are currently looking for new talents
Do you enjoy an international work environment and seek to drive change? Are you passionate about nanotechnology, sales, engineering and consider yourself to be a contributing team player? Check out our job opportunities below.
Sorrento Therapeutics highlights the Sofusa® Drug Delivery System in Covid-19 Vaccine Development program
The Sofusa® Drug Delivery System, for which Sorrento Therapeutics use Obducat’s NIL technology to fabricate the nanotopography draped microneedles, was highlighted in Sorrento Therapeutics proprietary mRNA vaccine development program for COVID-19.
Obducat customer Sorrento Therapeutics reports positive results
Sorrento Therapeutics, a biopharmaceutical company, reports positive initial result in dosing with the Sofusa® Lymphatic Drug Delivery Device. Sorrento Therapeutics use Obducat’s NIL technology to fabricate the nanotopography draped microneedles used in the Sofusa® Drug Delivery System.
Can nanoimprint processes prevent bacterial adhesion?
Vladislav Genevskiy, who is an Industrial PhD student investigates how different surface or topography patterns induced through Nanoimprint lithography may promote or inhibit the bacteria from growing.